Publicação
Uso de anticorpos monoclonais no tratamento da enxaqueca em idade pediátrica: uma realidade cada vez mais próxima?
| Resumo: | Migraine is a neurological disorder that has a high incidence and prevalence rate in children and adolescents, resulting in high costs and disability for the individual and community. Current preventive medications have variable effectiveness, and their use is often limited by undesirable side effects. The discovery of the role of calcitonin gene-related peptide (CGRP) in the pathophysiology of migraine led to the development of specific drugs against it or its receptor, which have already demonstrated efficacy and tolerability in the treatment of migraine in adults. Tolerability has been similar to placebo and, so far, there have been no worrying signs regarding the safety of these medicines. Scientific studies in the adult population have demonstrated unprecedented response rates, with studies identifying super-responders, with 100% improvements in metrics considered as primary and secondary objectives.However, little is known about these medications in the treatment of migraine in pediatrics. There are ongoing clinical trials aimed at using these drugs in children and adolescents, trying to assess whether the magnitude of the therapeutic effect will be similar to that seen in the adult population, as well as whether or not the safety profile will be superimposable. The objective of this review article is to gather the available information regarding these studies, showing the therapeutic potential of this pharmacological class in the treatment of migraine in pediatric age. |
|---|---|
| Autores principais: | Silva, Alexandra Maria Rodrigues da |
| Assunto: | Calcitonin gene-related peptide Migraine Monoclonal antibodies Children Adolescents Peptídeo relacionado com o gene da calcitonina Enxaqueca Anticorpos monoclonais Crianças Adolescentes |
| Ano: | 2024 |
| País: | Portugal |
| Tipo de documento: | dissertação de mestrado |
| Tipo de acesso: | acesso embargado |
| Instituição associada: | Universidade de Coimbra |
| Idioma: | português |
| Origem: | Estudo Geral - Universidade de Coimbra |
| Resumo: | Migraine is a neurological disorder that has a high incidence and prevalence rate in children and adolescents, resulting in high costs and disability for the individual and community. Current preventive medications have variable effectiveness, and their use is often limited by undesirable side effects. The discovery of the role of calcitonin gene-related peptide (CGRP) in the pathophysiology of migraine led to the development of specific drugs against it or its receptor, which have already demonstrated efficacy and tolerability in the treatment of migraine in adults. Tolerability has been similar to placebo and, so far, there have been no worrying signs regarding the safety of these medicines. Scientific studies in the adult population have demonstrated unprecedented response rates, with studies identifying super-responders, with 100% improvements in metrics considered as primary and secondary objectives.However, little is known about these medications in the treatment of migraine in pediatrics. There are ongoing clinical trials aimed at using these drugs in children and adolescents, trying to assess whether the magnitude of the therapeutic effect will be similar to that seen in the adult population, as well as whether or not the safety profile will be superimposable. The objective of this review article is to gather the available information regarding these studies, showing the therapeutic potential of this pharmacological class in the treatment of migraine in pediatric age. |
|---|